(3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-bromoprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-hydroxyprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17R)-3,6,6,13-tetramethyl-17-prop-1-en-2-yl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol

C72H119BrO4 — CID 159770430

IUPAC(3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-bromoprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-hydroxyprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17R)-3,6,6,13-tetramethyl-17-prop-1-en-2-yl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol
SMILESC=C(C)[C@H]1CC[C@H]2[C@@H]3CC(C)(C)[C@H]4C[C@](C)(O)CC[C@@H]4[C@H]3CC[C@]12C.C=C(CBr)[C@H]1CC[C@H]2[C@@H]3CC(C)(C)[C@H]4C[C@](C)(O)CC[C@@H]4[C@H]3CC[C@]12C.C=C(CO)[C@H]1CC[C@H]2[C@@H]3CC(C)(C)[C@H]4C[C@](C)(O)CC[C@@H]4[C@H]3CC[C@]12C
InChIInChI=1S/C24H39BrO.C24H40O2.C24H40O/c2*1-15(14-25)19-6-7-20-18-12-22(2,3)21-13-23(4,26)10-8-17(21)16(18)9-11-24(19,20)5;1-15(2)19-7-8-20-18-13-22(3,4)21-14-23(5,25)11-9-17(21)16(18)10-12-24(19,20)6/h16-21,26H,1,6-14H2,2-5H3;16-21,25-26H,1,6-14H2,2-5H3;16-21,25H,1,7-14H2,2-6H3/t3*16-,17-,18-,19-,20+,21+,23-,24-/m111/s1
InChIKeyNGARYDGJEOZRLP-XPTXWDCPSA-N
MW1128.64 g/mol
LogP18.00
Rot. Bonds5

About (3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-bromoprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-hydroxyprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17R)-3,6,6,13-tetramethyl-17-prop-1-en-2-yl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol

(3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-bromoprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-hydroxyprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17R)-3,6,6,13-tetramethyl-17-prop-1-en-2-yl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol (PubChem CID 159770430) has the molecular formula C72H119BrO4 and a molecular weight of 1128.64 g/mol. Its IUPAC name is (3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-bromoprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-hydroxyprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17R)-3,6,6,13-tetramethyl-17-prop-1-en-2-yl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol.

Molecular Properties

Compound Name(3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-bromoprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-hydroxyprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17R)-3,6,6,13-tetramethyl-17-prop-1-en-2-yl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol
PubChem CID159770430
Molecular FormulaC72H119BrO4
Molecular Weight1128.64 g/mol
Exact Mass1126.83
IUPAC Name(3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-bromoprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-hydroxyprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17R)-3,6,6,13-tetramethyl-17-prop-1-en-2-yl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol
SMILESC=C(C)[C@H]1CC[C@H]2[C@@H]3CC(C)(C)[C@H]4C[C@](C)(O)CC[C@@H]4[C@H]3CC[C@]12C.C=C(CBr)[C@H]1CC[C@H]2[C@@H]3CC(C)(C)[C@H]4C[C@](C)(O)CC[C@@H]4[C@H]3CC[C@]12C.C=C(CO)[C@H]1CC[C@H]2[C@@H]3CC(C)(C)[C@H]4C[C@](C)(O)CC[C@@H]4[C@H]3CC[C@]12C
InChIInChI=1S/C24H39BrO.C24H40O2.C24H40O/c2*1-15(14-25)19-6-7-20-18-12-22(2,3)21-13-23(4,26)10-8-17(21)16(18)9-11-24(19,20)5;1-15(2)19-7-8-20-18-13-22(3,4)21-14-23(5,25)11-9-17(21)16(18)10-12-24(19,20)6/h16-21,26H,1,6-14H2,2-5H3;16-21,25-26H,1,6-14H2,2-5H3;16-21,25H,1,7-14H2,2-6H3/t3*16-,17-,18-,19-,20+,21+,23-,24-/m111/s1
InChIKeyNGARYDGJEOZRLP-XPTXWDCPSA-N
XLogP18.00
TPSA80.92 Ų
H-Bond Donors4
H-Bond Acceptors4
Rotatable Bonds5
Heavy Atoms77
Complexity

Lipinski Rule of Five

2 violations

RuleValue
MW ≤ 5001128.64
LogP ≤ 518.00
H-Bond Donors ≤ 54
H-Bond Acceptors ≤ 104

Computed Properties (RDKit)

Structural Alerts{'alert_name': 'alkyl_halide', 'substructure': 'N/A'}, {'alert_name': 'isolated_alkene', 'substructure': 'N/A'}

Analyze (3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-bromoprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-hydroxyprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17R)-3,6,6,13-tetramethyl-17-prop-1-en-2-yl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol with MolForge

Explore ADMET properties, 3D molecular structure, drug-likeness score, and discover similar compounds using our AI-powered platform.

Launch Full Analysis

Related Compounds

Frequently Asked Questions

What is the IUPAC name of (3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-bromoprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-hydroxyprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17R)-3,6,6,13-tetramethyl-17-prop-1-en-2-yl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol?
The IUPAC name of (3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-bromoprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-hydroxyprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17R)-3,6,6,13-tetramethyl-17-prop-1-en-2-yl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol (CID 159770430) is (3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-bromoprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-hydroxyprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17R)-3,6,6,13-tetramethyl-17-prop-1-en-2-yl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol.
What is the SMILES notation for (3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-bromoprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-hydroxyprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17R)-3,6,6,13-tetramethyl-17-prop-1-en-2-yl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol?
The canonical SMILES for (3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-bromoprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-hydroxyprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17R)-3,6,6,13-tetramethyl-17-prop-1-en-2-yl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol is C=C(C)[C@H]1CC[C@H]2[C@@H]3CC(C)(C)[C@H]4C[C@](C)(O)CC[C@@H]4[C@H]3CC[C@]12C.C=C(CBr)[C@H]1CC[C@H]2[C@@H]3CC(C)(C)[C@H]4C[C@](C)(O)CC[C@@H]4[C@H]3CC[C@]12C.C=C(CO)[C@H]1CC[C@H]2[C@@H]3CC(C)(C)[C@H]4C[C@](C)(O)CC[C@@H]4[C@H]3CC[C@]12C.
What is the InChIKey of (3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-bromoprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-hydroxyprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17R)-3,6,6,13-tetramethyl-17-prop-1-en-2-yl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol?
The InChIKey is NGARYDGJEOZRLP-XPTXWDCPSA-N. The full InChI is InChI=1S/C24H39BrO.C24H40O2.C24H40O/c2*1-15(14-25)19-6-7-20-18-12-22(2,3)21-13-23(4,26)10-8-17(21)16(18)9-11-24(19,20)5;1-15(2)19-7-8-20-18-13-22(3,4)21-14-23(5,25)11-9-17(21)16(18)10-12-24(19,20)6/h16-21,26H,1,6-14H2,2-5H3;16-21,25-26H,1,6-14H2,2-5H3;16-21,25H,1,7-14H2,2-6H3/t3*16-,17-,18-,19-,20+,21+,23-,24-/m111/s1.
What are the key properties of (3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-bromoprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-hydroxyprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17R)-3,6,6,13-tetramethyl-17-prop-1-en-2-yl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol?
(3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-bromoprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-hydroxyprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17R)-3,6,6,13-tetramethyl-17-prop-1-en-2-yl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol has a molecular weight of 1128.64 g/mol, XLogP of 18.00, 5 rotatable bonds, 4 hydrogen bond donors, and 4 hydrogen bond acceptors.
Where does this data come from?
All data for (3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-bromoprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17S)-17-(3-hydroxyprop-1-en-2-yl)-3,6,6,13-tetramethyl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol;(3R,5S,8R,9R,10R,13S,14S,17R)-3,6,6,13-tetramethyl-17-prop-1-en-2-yl-1,2,4,5,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-ol is sourced from PubChem (CID 159770430), the world's largest open chemistry database maintained by the National Library of Medicine (NIH).